IP Library Assignment 059809/0557
Patent Assignment
Reel/Frame 059809/0557

Change of Name

Recorded: 2022-04-27 Pages: 6
Assignor
Assignee
SUMITOMO PHARMA ONCOLOGY, INC.
640 MEMORIAL DRIVE, CAMBRIDGE, MASSACHUSETTS, 02139
Covered Properties (44)
Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the Axl Kinase
Patent: 8,901,120 →
Application: 13/436,910 →
Publication: US 2012/0283261
PKM2 Modulators and Methods for Their Use
Patent: 9,394,257 →
Application: 14/435,976 →
Publication: US 2015/0344436
Predicting Response to Alvocidib by Mitochondrial Profiling
Patent: 9,901,574 →
Application: 15/134,051 →
Publication: US 2016/0303101
Alvocidib Prodrugs Having Increased Bioavailability
Patent: 9,758,539 →
Application: 15/158,206 →
Publication: US 2016/0340376
PKM2 Modulators and Methods for Their Use
Application: 15/183,581 →
Publication: US 2017/0015631
Alvocidib Prodrugs Having Increased Bioavailability
Application: 15/673,213 →
Publication: US 2017/0334938
Combination Therapies for Treatment of Cancer
Application: 15/750,151 →
Publication: US 2018/0256580
Profiling Peptides and Methods for Sensitivity Profiling
Application: 15/847,697 →
Publication: US 2018/0172673
Profiling Peptides and Methods for Sensitivity Profiling
Application: 16/023,360 →
Publication: US 2018/0299432
Predicting Response to Alvocidib by Mitochondrial Profiling
Application: 16/132,270 →
Publication: US 2019/0030017
PKM2 Modulators and Methods for Their Use
Application: 16/226,599 →
Publication: US 2019/0119219
Profiling Peptides and Methods for Sensitivity Profiling
Application: 16/279,623 →
Publication: US 2019/0178873
Alvocidib Prodrugs Having Increased Bioavailability
Application: 16/279,958 →
Publication: US 2019/0177350
Axl Kinase Inhibitors and Use of the Same
Application: 16/376,452 →
Predicting Response to Alvocidib by Mitochondrial Profiling
Application: 16/425,826 →
Publication: US 2019/0282557
Alvocidib Prodrugs and Their Use as Protein Kinase Inhibitors
Application: 16/462,094 →
Publication: US 2020/0048228
PKM2 Modulators and Methods for Their Use
Application: 16/584,912 →
Publication: US 2020/0109120
Treatment Regimen for Cancers That Are Insensitive to Bcl-2 Inhibitors Using the Mcl-1 Inhibitor Alvocidib
Application: 16/646,853 →
Publication: US 2020/0276215
Combination Therapies for Treatment of Cancer
Application: 16/665,277 →
Publication: US 2020/0054642
CDK9 Inhibitors and Polymorphs Thereof for Use as Agents for Treatment of Cancer
Application: 16/703,773 →
Publication: US 2020/0255462
Methods to Target Transcriptional Control at Super-Enhancer Regions
Application: 16/730,810 →
Publication: US 2020/0316084
PKM2 Activators in Combination with Reactive Oxygen Species for Treatment of Cancer
Application: 16/755,868 →
Publication: US 2020/0237766
Combination Therapies for Treatment of Cancer
Application: 16/821,762 →
Publication: US 2020/0215071
Compositions Comprising PKM2 Modulators and Methods of Treatment Using the Same
Application: 16/826,131 →
Publication: US 2020/0297698
Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof
Application: 16/919,853 →
Publication: US 2021/0000825
PKM2 Modulators and Methods for Their Use
Application: 16/930,254 →
Publication: US 2021/0002233
Materials and Methods for Treating Cancer
Application: 17/045,411 →
Publication: US 2021/0145830
Combination Therapies for Treatment of Cancer
Application: 17/061,821 →
Publication: US 2021/0228582
Axl Kinase Inhibitors and Use of the Same
Application: 17/092,521 →
Publication: US 2021/0205304
CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer
Application: 17/225,836 →
Publication: US 2021/0332071
Deuterated Alvocidib and Alvocidib Prodrugs
Application: 17/253,603 →
Publication: US 2021/0277037
Methods for Monitoring Tumor Lysis Syndrome
Application: 17/284,409 →
Publication: US 2021/0379042
Alvocidib Prodrugs Having Increased Bioavailability
Application: 17/314,896 →
Publication: US 2021/0261585
Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure
Application: 17/435,264 →
Publication: US 2022/0125776
PKM2 Modulators and Methods for Their Use
Application: 17/439,611 →
Publication: US 2022/0162200
Methods for Treating Castration-Resistant and Castration-Sensitive Prostate Cancer
Application: 17/547,799 →
Publication: US 2022/0339172
Treatment of Cancer
Application: 17/596,805 →
Publication: US 2022/0305037
Treatment of Cancer
Application: 17/596,807 →
Publication: US 2022/0257581
Axl Inhibitor Formulations
Application: 17/761,993 →
Publication: US 2022/0380348
Alk-5 Inhibitors and Uses Thereof
Application: 63/166,610 →
Alk-5 Inhibitors and Uses Thereof
Application: 63/166,621 →
(Furopyrimidin-4-yl)piperazine Compounds and Uses Thereof
Application: 63/166,852 →
Alk-5 Inhibitors and Uses Thereof
Application: 63/215,122 →
Imidazo[1,2-B]Pyridazinyl Compounds and Uses Thereof
Application: 63/227,579 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Aug 15, 2013
From: BEARSS, DAVID J.; VANKAYALAPATI, HARIPRASAD; MOLLARD, ALEXIS; WARNER, STEVEN L.
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 031021/0171 →
Assignment of Assignor's Interest Nov 10, 2015
From: HO, KOC-KAN; XU, YONG; SAUNDERS, MICHAEL DAVID; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 037005/0571 →
Assignment of Assignor's Interest Aug 5, 2016
From: SIDDIQUI-JAIN, ADAM; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 039358/0432 →
Assignment of Assignor's Interest Aug 31, 2016
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 039601/0719 →
Security Interest Nov 17, 2016
From: TOLERO PHARMACEUTICALS, INC.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 040362/0884 →
Assignment of Assignor's Interest Mar 15, 2018
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; PETERSON, PETER W.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 045238/0259 →
Assignment of Assignor's Interest Apr 24, 2018
From: BEARSS, DAVID J.; WARNER, STEVEN L.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 045626/0176 →
Assignment of Assignor's Interest Dec 19, 2018
From: HO, KOC-KAN; XU, YONG; SAUNDERS, MICHAEL DAVID; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 047959/0693 →
Assignment of Assignor's Interest Jan 17, 2019
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; PETERSON, PETER W.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 048379/0095 →
Assignment of Assignor's Interest Jul 17, 2019
From: SUMITOMO DAINIPPON PHARMA COMPANY, LIMITED
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 049775/0631 →
Assignment of Assignor's Interest Jul 17, 2019
From: SIDDIQUI-JAIN, ADAM
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 049774/0387 →
Assignment of Assignor's Interest Jul 17, 2019
From: SAWAYAMA, YUSUKE; HIROSE, WATARU; BAN, HITOSHI
To: SUMITOMO DAINIPPON PHARMA COMPANY, LIMITED
Reel/Frame 049774/0933 →
Assignment of Assignor's Interest Jul 17, 2019
From: SUMITOMO DAINIPPON PHARMA COMPANY, LIMITED
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 049775/0023 →
Assignment of Assignor's Interest Jul 17, 2019
From: SIDDIQUI-JAIN, ADAM; WARNER, STEVEN L.; FLYNN, PAUL; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 049775/0391 →
Assignment of Assignor's Interest Jul 17, 2019
From: TOMIMATSU, NOZOMI; FUJIMURA, KEN; UMEHARA, HIROKI; NONOYAMA, AKIHITO
To: SUMITOMO DAINIPPON PHARMA COMPANY, LIMITED
Reel/Frame 049775/0543 →
Assignment of Assignor's Interest Aug 7, 2019
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; PETERSON, PETER W.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 049995/0266 →
Assignment of Assignor's Interest Dec 23, 2019
From: SIDDIQUI-JAIN, ADAM; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 051356/0527 →
Assignment of Assignor's Interest Feb 19, 2020
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 051855/0587 →
Assignment of Assignor's Interest Feb 21, 2020
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 051883/0725 →
Assignment of Assignor's Interest Apr 27, 2020
From: HO, KOC-KAN; XU, YONG; SAUNDERS, MICHAEL DAVID; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 052500/0057 →
Change of Name Jul 10, 2020
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 053184/0713 →
Change of Name Jul 10, 2020
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 053184/0705 →
Change of Name Jul 10, 2020
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 053184/0684 →
Change of Name Jul 10, 2020
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 053181/0133 →
Merger Jul 10, 2020
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 053181/0114 →